patritumab deruxtecan + pembrolizumab

Patritumab deruxtecan + pembrolizumab is an experimental combination therapy comprising **patritumab deruxtecan**, an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 3 (HER3), and **pembrolizumab**, a programmed death-1 (PD-1) immune checkpoint inhibitor. Patritumab deruxtecan consists of a fully human anti-HER3 monoclonal antibody conjugated via a cleavable tetrapeptide linker to a topoisomerase I inhibitor payload (DXd) designed to deliver cytotoxic activity selectively to HER3-expressing tumor cells. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor, blocking its interaction with PD-L1 and PD-L2, thereby enhancing the immune response against tumor cells. The combination is under evaluation in clinical trials for high-risk early-stage triple-negative or hormone receptor-low positive/HER2-negative breast cancer, aiming to improve pathological complete response rates and long-term outcomes[2][3].

Other names

HERTHENA-Breast-03HERTHENA-Breast03HERTHENA-Breast 03